Literature DB >> 24753592

Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.

Lihong Chen1, Guangrui Yang, James Monslow, Leslie Todd, David P Cormode, Jun Tang, Gregory R Grant, Jonathan H DeLong, Soon Yew Tang, John A Lawson, Ellen Pure, Garret A Fitzgerald.   

Abstract

Microsomal prostaglandin E synthase-1 (mPGES-1) in myeloid and vascular cells differentially regulates the response to vascular injury, reflecting distinct effects of mPGES-1-derived PGE2 in these cell types on discrete cellular components of the vasculature. The cell selective roles of mPGES-1 in atherogenesis are unknown. Mice lacking mPGES-1 conditionally in myeloid cells (Mac-mPGES-1-KOs), vascular smooth muscle cells (VSMC-mPGES-1-KOs), or endothelial cells (EC-mPGES-1-KOs) were crossed into hyperlipidemic low-density lipoprotein receptor-deficient animals. En face aortic lesion analysis revealed markedly reduced atherogenesis in Mac-mPGES-1-KOs, which was concomitant with a reduction in oxidative stress, reflective of reduced macrophage infiltration, less lesional expression of inducible nitric oxide synthase (iNOS), and lower aortic expression of NADPH oxidases and proinflammatory cytokines. Reduced oxidative stress was reflected systemically by a decline in urinary 8,12-iso-iPF2α-VI. In contrast to exaggeration of the response to vascular injury, deletion of mPGES-1 in VSMCs, ECs, or both had no detectable phenotypic impact on atherogenesis. Macrophage foam cell formation and cholesterol efflux, together with plasma cholesterol and triglycerides, were unchanged as a function of genotype. In conclusion, myeloid cell mPGES-1 promotes atherogenesis in hyperlipidemic mice, coincident with iNOS-mediated oxidative stress. By contrast, mPGES-1 in vascular cells does not detectably influence atherogenesis in mice. This strengthens the therapeutic rationale for targeting macrophage mPGES-1 in inflammatory cardiovascular diseases.

Entities:  

Keywords:  atherosclerosis; prostanoid

Mesh:

Substances:

Year:  2014        PMID: 24753592      PMCID: PMC4020105          DOI: 10.1073/pnas.1401797111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Authors:  Christopher P Cannon; Sean P Curtis; Garret A FitzGerald; Henry Krum; Amarjot Kaur; James A Bolognese; Alise S Reicin; Claire Bombardier; Michael E Weinblatt; Désirée van der Heijde; Erland Erdmann; Loren Laine
Journal:  Lancet       Date:  2006-11-18       Impact factor: 79.321

2.  Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method.

Authors:  Wen-Liang Song; John A Lawson; Miao Wang; Helen Zou; Garret A FitzGerald
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

3.  Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation.

Authors:  Miao Wang; Eric Lee; Wenliang Song; Emanuela Ricciotti; Daniel J Rader; John A Lawson; Ellen Puré; Garret A FitzGerald
Journal:  Circulation       Date:  2008-02-19       Impact factor: 29.690

4.  Microsomal prostaglandin synthase-1-derived prostaglandin E2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress.

Authors:  Zhanjun Jia; Xiaohua Guo; Hui Zhang; Mong-Heng Wang; Zheng Dong; Tianxin Yang
Journal:  Hypertension       Date:  2008-09-29       Impact factor: 10.190

5.  Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction.

Authors:  Norbert Degousee; Shafie Fazel; Denis Angoulvant; Eva Stefanski; Sven-Christian Pawelzik; Marina Korotkova; Sara Arab; Peter Liu; Thomas F Lindsay; Sun Zhuo; Jagdish Butany; Ren-Ke Li; Laurent Audoly; Ronald Schmidt; Carlo Angioni; Gerd Geisslinger; Per-Johan Jakobsson; Barry B Rubin
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 6.  Prostanoids in health and disease.

Authors:  Emer M Smyth; Tilo Grosser; Miao Wang; Ying Yu; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2008-12-17       Impact factor: 5.922

7.  Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.

Authors:  Nobuo Nagai; Marc F Hoylaerts; David J Gallacher; Hua Rong Lu; H Roger Lijnen
Journal:  Thromb Res       Date:  2008-06-20       Impact factor: 3.944

Review 8.  Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.

Authors:  M Wang; W-L Song; Y Cheng; G A Fitzgerald
Journal:  J Intern Med       Date:  2008-05       Impact factor: 8.989

9.  Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis.

Authors:  Mei Chen; Eric Boilard; Peter A Nigrovic; Patsy Clark; Daigen Xu; Garret A Fitzgerald; Laurent P Audoly; David M Lee
Journal:  Arthritis Rheum       Date:  2008-05

10.  Role of microsomal prostaglandin E synthase 1 in the kidney.

Authors:  Helene Francois; Carie Facemire; Anil Kumar; Laurent Audoly; Beverly Koller; Thomas Coffman
Journal:  J Am Soc Nephrol       Date:  2007-04-18       Impact factor: 10.121

View more
  16 in total

Review 1.  PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Authors:  Rania Nasrallah; Ramzi Hassouneh; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

2.  Bmal1 Deletion in Myeloid Cells Attenuates Atherosclerotic Lesion Development and Restrains Abdominal Aortic Aneurysm Formation in Hyperlipidemic Mice.

Authors:  Guangrui Yang; Jiayang Zhang; Tingting Jiang; James Monslow; Soon Yew Tang; Leslie Todd; Ellen Puré; Lihong Chen; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-23       Impact factor: 8.311

Review 3.  Prostanoids and NSAIDs in cardiovascular biology and disease.

Authors:  Babettte B Weksler
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

4.  Lipopolysaccharide (LPS)-mediated priming of toll-like receptor 4 enhances oxidant-induced prostaglandin E2 biosynthesis in primary murine macrophages.

Authors:  Yan Zhang; Orisa J Igwe
Journal:  Int Immunopharmacol       Date:  2017-11-20       Impact factor: 4.932

5.  Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the inflammatory diseases.

Authors:  Qian Wang; Yuanyuan Li; Mengying Wu; Songming Huang; Aihua Zhang; Yue Zhang; Zhanjun Jia
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

6.  Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension.

Authors:  M S Avendaño; S Martínez-Revelles; A Aguado; M R Simões; M González-Amor; R Palacios; P Guillem-Llobat; D V Vassallo; L Vila; J García-Puig; L M Beltrán; M J Alonso; M V Cachofeiro; M Salaices; A M Briones
Journal:  Br J Pharmacol       Date:  2016-03-21       Impact factor: 8.739

7.  Myeloid Cell mPges-1 Deletion Attenuates Mortality Without Affecting Remodeling After Acute Myocardial Infarction in Mice.

Authors:  Lihong Chen; Guangrui Yang; Tingting Jiang; Soon Yew Tang; Tao Wang; Qing Wan; Miao Wang; Garret A FitzGerald
Journal:  J Pharmacol Exp Ther       Date:  2019-04-16       Impact factor: 4.030

8.  Targeted delivery of mPGES-1 inhibitors to macrophages via the folate receptor-β for inflammatory pain.

Authors:  Liudmila L Mazaleuskaya; Seokwoo Lee; Hu Meng; Jeffrey D Winkler; Garret A FitzGerald
Journal:  Bioorg Med Chem Lett       Date:  2021-08-12       Impact factor: 2.940

Review 9.  Lipoproteins and lipoprotein mimetics for imaging and drug delivery.

Authors:  C Shad Thaxton; Jonathan S Rink; Pratap C Naha; David P Cormode
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

10.  Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation.

Authors:  Jun Tang; Mark E Lobatto; Laurien Hassing; Susanne van der Staay; Sarian M van Rijs; Claudia Calcagno; Mounia S Braza; Samantha Baxter; Francois Fay; Brenda L Sanchez-Gaytan; Raphaël Duivenvoorden; Hendrik Sager; Yaritzy M Astudillo; Wei Leong; Sarayu Ramachandran; Gert Storm; Carlos Pérez-Medina; Thomas Reiner; David P Cormode; Gustav J Strijkers; Erik S G Stroes; Filip K Swirski; Matthias Nahrendorf; Edward A Fisher; Zahi A Fayad; Willem J M Mulder
Journal:  Sci Adv       Date:  2015-04       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.